Compare · GLUE vs RVMD
GLUE vs RVMD
Side-by-side comparison of Monte Rosa Therapeutics Inc. (GLUE) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GLUE and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $39.58B, about 19.1x GLUE ($2.07B).
- Over the past year, GLUE is up 313.5% and RVMD is up 385.9% - RVMD leads by 72.4 points.
- RVMD has been more active in the news (15 items in the past 4 weeks vs 14 for GLUE).
- RVMD has more recent analyst coverage (25 ratings vs 11 for GLUE).
- Company
- Monte Rosa Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $24.54+5.87%
- $186.14+3.91%
- Market cap
- $2.07B
- $39.58B
- 1M return
- +38.25%
- +18.88%
- 1Y return
- +313.48%
- +385.88%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 14
- 15
- Recent ratings
- 11
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest GLUE
- President & CEO Warmuth Markus sold $220,219 worth of shares (9,500 units at $23.18), decreasing direct ownership by 2% to 585,038 units (SEC Form 4)
- Chief Operating Officer Champoux Jennifer exercised 4,351 shares at a strike of $3.98 and sold $101,730 worth of shares (4,351 units at $23.38) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
- Chief Scientific Officer Townson Sharon exercised 6,000 shares at a strike of $6.14 and sold $139,849 worth of shares (6,000 units at $23.31) as part of a pre-agreed trading plan (SEC Form 4)
- Director Behbahani Ali disposed of 1,015,000 shares and acquired 15,000 shares (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.
- Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Medical Officer Janku Filip exercised 5,407 shares at a strike of $13.41 and sold $132,472 worth of shares (5,407 units at $24.50) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Janku Filip exercised 6,000 shares at a strike of $7.56 and sold $137,700 worth of shares (6,000 units at $22.95) as part of a pre-agreed trading plan (SEC Form 4)
- Director Manning Anthony M. exercised 10,000 shares at a strike of $4.16 and sold $231,100 worth of shares (10,000 units at $23.11) (SEC Form 4)
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)